CN106109411A - 姜黄素滴眼液及其制备方法 - Google Patents
姜黄素滴眼液及其制备方法 Download PDFInfo
- Publication number
- CN106109411A CN106109411A CN201610547678.0A CN201610547678A CN106109411A CN 106109411 A CN106109411 A CN 106109411A CN 201610547678 A CN201610547678 A CN 201610547678A CN 106109411 A CN106109411 A CN 106109411A
- Authority
- CN
- China
- Prior art keywords
- curcumin
- eye drop
- emulsifying agent
- emulsion
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims abstract description 58
- 229940109262 curcumin Drugs 0.000 title claims abstract description 29
- 235000012754 curcumin Nutrition 0.000 title claims abstract description 29
- 239000004148 curcumin Substances 0.000 title claims abstract description 29
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 239000003889 eye drop Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 23
- 239000000839 emulsion Substances 0.000 claims abstract description 17
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 8
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims abstract description 6
- 241000234314 Zingiber Species 0.000 claims abstract description 4
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 4
- 230000009514 concussion Effects 0.000 claims abstract description 4
- 235000008397 ginger Nutrition 0.000 claims abstract description 4
- 125000001967 indiganyl group Chemical group [H][In]([H])[*] 0.000 claims abstract description 4
- 239000011780 sodium chloride Substances 0.000 claims abstract description 4
- -1 fatty acid ester Chemical class 0.000 claims description 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 229920000223 polyglycerol Polymers 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 3
- 229940113124 polysorbate 60 Drugs 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 4
- 230000002980 postoperative effect Effects 0.000 description 13
- 238000001914 filtration Methods 0.000 description 8
- 230000037390 scarring Effects 0.000 description 8
- 208000010412 Glaucoma Diseases 0.000 description 6
- 208000002352 blister Diseases 0.000 description 6
- 239000006196 drop Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004410 intraocular pressure Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 241000723377 Coffea Species 0.000 description 3
- 210000000589 cicatrix Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了姜黄素滴眼液的制备方法，包括以下步骤：(1)制备乳液：用高精度量筒分别量取一定量H2O倒入广口瓶中，选取适当的乳化剂，然后震荡容器使乳化剂完全溶解在H2O中；(2)乳化处理：称取一定质量分数的姜黄素，将其倒入步骤(1)中制备的乳液中，用高剪切乳化机做乳化处理；(3)取适量姜黄素乳状液溶于0.9％氯化钠溶液得到姜黄素滴眼液。本发明还公开了一种由上述方法制备而成的姜黄素滴眼液。
Description
技术领域
本发明涉及医药技术领域，具体涉及一种具有抑制小梁切除术后滤过瘢痕化作用的姜黄素滴眼液。
背景技术
小梁切除手术是最常用的抗青光眼手术方法。术后结膜瓣瘢痕化是造成手术失败的主要原因。有些年轻患者或再次进行小梁切除手术的患者，即使术中使用丝裂霉素C(mitomycinC,MMC)预防瘢痕生成，仍可能出现术后滤过泡形成失败。小梁切除术后的滤过瘢痕化问题,仍是目前困扰青光眼医生的难题，因此，寻找安全、有效、副作用小的抗瘢痕药物意义重大。研究表明，姜黄素具有抗炎症、抗氧化、抗肿瘤的作用，因此可能具有抑制小梁切除术后滤过瘢痕化作用。
发明内容
本发明的目的在于避免现有技术中的上述不足之处而提供姜黄素滴眼液及其制备方法。
本发明的目的通过以下技术方案实现：
提供了姜黄素滴眼液的制备方法，其特征在于：包括以下步骤：(1)制备乳液：用高精度量筒分别量取一定量H2O倒入广口瓶中，选取适当的乳化剂，然后震荡容器使乳化剂完全溶解在H2O中；(2)乳化处理：称取一定质量分数的姜黄素，将其倒入步骤(1)中制备的乳液中，用高剪切乳化机做乳化处理；(3)取适量姜黄素乳状液溶于0.9％氯化钠溶液得到姜黄素滴眼液。
优选地，所述乳化剂为水包油乳化剂。
优选地，所述乳化剂包括但不限于聚山梨醇酯60，聚山梨醇酯80，聚甘油脂肪酸酯，单甘酯，蔗糖酯和/或聚甘油脂肪酸酯。
本发明所提供的实施例的有益效果：
本发明的实施例所提供的一种姜黄素滴眼液的制备方法，在油-水体系中加入乳化剂,在降低表面张力的同时必然在界面上吸附并形成界面膜，此膜有一定的强度，加入带有亲水和亲油基团的保护分散相液滴，可使体系内发生分子相互碰撞而不宜合并；另外由于吸附和摩擦，液滴带电而形成双电层结构，液滴双电层的排斥作用使得液滴难以聚集，提高乳状液的稳定性。利用上述方法制成的姜黄素滴眼液，具有安全有效、副作用小的抗瘢痕药物意义重大；姜黄素具有抗炎症、抗氧化、抗肿瘤的作用，因此具有抑制小梁切除术后滤过瘢痕化作用。
附图说明
利用附图对发明作进一步说明，但附图中的实施例不构成对本发明的任何限制，对于本领域的普通技术人员，在不付出创造性劳动的前提下，还可以根据以下附图获得其它的附图。
图1是本发明的姜黄素乳状液配置流程图。
具体实施方式
结合以下实施例对本发明作进一步描述。
姜黄素是非水溶性有机物质,与水混合后无法长时间保持稳定状态。要使二者混溶并保持相对稳定，就必须加入同时带有亲水基团和亲油基团的表面活性物质。在油-水体系中加入乳化剂,它们在降低表面张力的同时必然在界面上吸附并形成界面膜，此膜有一定的强度，加入带有亲水和亲油基团的保护分散相液滴，可使体系内发生分子相互碰撞而不宜合并；另外由于吸附和摩擦，液滴带电而形成双电层结构，液滴双电层的排斥作用使得液滴难以聚集，因而可提高乳状液的稳定性。
本发明的实施例所提供的姜黄素滴眼液，可用于治疗小梁切除术后滤过瘢痕化，如图1所示，其制备方法如下：
(1)制备乳液：用高精度量筒分别量取一定量H2O倒入广口瓶中，选取适当的乳化剂,然后震荡容器使乳化剂完全溶解在H2O中；(2)乳化处理：用天平称取一定质量分数的姜黄素，将其倒入步骤(1)中制备的乳液中，用高剪切乳化机做乳化处理，根据相似相溶原理,欲使油相分散，要求乳化剂的憎水基团与油的结构及性质越相似越好，这样的乳化剂与分散相的亲和力强、分散效果好，乳化剂的用量也少。在不限定乳化剂的情况下，为得到较好的乳化效果，可将不同的乳化剂混合使用；(3)取适量姜黄素乳状液溶于0.9％氯化钠溶液得到姜黄素滴眼液。
优选地，所述乳化剂为水包油乳化剂。
优选地，所述乳化剂包括但不限于聚山梨醇酯60，聚山梨醇酯80，聚甘油脂肪酸酯，单甘酯，蔗糖酯和/或聚甘油脂肪酸酯。
此外，本申请还提供了一种姜黄素滴眼液，其根据上述方法制备而成。
本发明姜黄素滴眼液经动物实验证明：对兔小梁切除术后能减少术后结膜巩膜间得瘢痕化，保持滤过道通畅，滤过泡存活更持久，因此可以用作抑制小梁切除术后滤过瘢痕化的药物。
实验如下：
采用动物实验：实验动物：新西兰白兔，体重2.0-2.5kg，雌雄不限，检查无眼部疾患及全身器质性疾病。
进行常规小梁切除手术，成功建模12只，随机分为A﹑B两组，分别予以编号。A组作为用药组，给予姜黄素滴眼液，编号为A1﹑A2﹑A3﹑A4﹑A5﹑A6；B组作为阴性对照组，给予0.9％氯化钠注射液，编号为B1﹑B2﹑B3﹑B4﹑B5﹑B6。给药方式均为滴眼，1滴/次，3次/日，连续28天。在制备模型后的D1﹑D7﹑D14﹑D21和D24采用裂隙灯显微镜数字图像处理系统进行拍照，并对滤过泡情况进行评分，同时测量眼压。
术后第1天、7天和14天两组滤过泡评分比较，差异无统计学意义；术后21天和28天两组滤过泡评分比较，差异具有统计学意义。术后两组的眼压较术前均有所下降，术后前期眼压下降明显，随着时间延长眼压逐渐升高。术前、术后1天、7天，两组见眼压差异没有统计学意义；术后14天、21天、28天眼压差异具有统计学意义。
上述实验结果表明，本发明姜黄素滴眼液可减轻兔小梁切除术后滤过通道的瘢痕化，增加滤过泡的存活时间，所以本发明可用作抑制小梁切除术后瘢痕化的治疗药物。
最后应当说明的是，以上实施例仅用以说明本发明的技术方案，而非对本发明保护范围的限制，尽管参照较佳实施例对本发明作了详细地说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的实质和范围。
Claims (4)
1.姜黄素滴眼液的制备方法，其特征在于：包括以下步骤：
(1)制备乳液：用高精度量筒分别量取一定量H2O倒入广口瓶中，选取适当的乳化剂，然后震荡容器使乳化剂完全溶解在H2O中；
(2)乳化处理：称取一定质量分数的姜黄素，将其倒入步骤(1)中制备的乳液中，用高剪切乳化机做乳化处理；
(3)取适量姜黄素乳状液溶于0.9％氯化钠溶液得到姜黄素滴眼液。
2.根据权利要求1所述的姜黄素滴眼液的制备方法，其特征在于：所述乳化剂为水包油乳化剂。
3.根据权利要求2所述的姜黄素滴眼液的制备方法，其特征在于：所述乳化剂包括但不限于聚山梨醇酯60，聚山梨醇酯80，聚甘油脂肪酸酯，单甘酯，蔗糖酯和/或聚甘油脂肪酸酯。
4.一种通过根据权利要求1-3任一所述的姜黄素滴眼液的制备方法制备的姜黄素滴眼液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610547678.0A CN106109411A (zh) | 2016-07-12 | 2016-07-12 | 姜黄素滴眼液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610547678.0A CN106109411A (zh) | 2016-07-12 | 2016-07-12 | 姜黄素滴眼液及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106109411A true CN106109411A (zh) | 2016-11-16 |
Family
ID=57282949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610547678.0A Pending CN106109411A (zh) | 2016-07-12 | 2016-07-12 | 姜黄素滴眼液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106109411A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102283373A (zh) * | 2011-08-30 | 2011-12-21 | 河南中大生物工程有限公司 | 一种姜黄素制剂的制备方法 |
| CN102361552A (zh) * | 2009-03-23 | 2012-02-22 | 莱拉制药用品私营有限责任公司 | 用于治疗过敏性眼/鼻疾病的姜黄色素及其代谢物 |
| US20120093894A1 (en) * | 2009-06-02 | 2012-04-19 | Abbott Medical Optics Inc. | Stable cyclosporine containing ophthalmic emulsion for treating dry eyes |
| CN104397673A (zh) * | 2014-10-23 | 2015-03-11 | 西安莹朴生物科技股份有限公司 | 姜黄色素微胶囊的制备方法 |
-
2016
- 2016-07-12 CN CN201610547678.0A patent/CN106109411A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102361552A (zh) * | 2009-03-23 | 2012-02-22 | 莱拉制药用品私营有限责任公司 | 用于治疗过敏性眼/鼻疾病的姜黄色素及其代谢物 |
| US20120093894A1 (en) * | 2009-06-02 | 2012-04-19 | Abbott Medical Optics Inc. | Stable cyclosporine containing ophthalmic emulsion for treating dry eyes |
| CN102283373A (zh) * | 2011-08-30 | 2011-12-21 | 河南中大生物工程有限公司 | 一种姜黄素制剂的制备方法 |
| CN104397673A (zh) * | 2014-10-23 | 2015-03-11 | 西安莹朴生物科技股份有限公司 | 姜黄色素微胶囊的制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shah et al. | Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs | |
| TWI478730B (zh) | 眼科乳劑 | |
| CA2585748C (en) | Dry eye emulsion | |
| Pathak et al. | Design and development of a novel pH triggered nanoemulsified in-situ ophthalmic gel of fluconazole: ex-vivo transcorneal permeation, corneal toxicity and irritation testing | |
| JP2021107402A (ja) | 眼科用薬物送達のための自己乳化薬物送達システム（ｓｅｄｄｓ） | |
| IL190497A0 (en) | Ophthalmic emulsions containing prostaglandins | |
| RU2002111336A (ru) | Дисперсии для изготовления композиций со слабо или плохо растворимыми агентами | |
| EP2978409B1 (en) | Ophthalmic composition, method for preparing the same, and use of the same | |
| EP2611414B1 (en) | A water-in-oil type emulsion for treating a disease of the eye | |
| CN109996538B (zh) | 眼科用组合物和其制造方法 | |
| Gohil et al. | Optimization of brinzolamide loaded microemulsion using formulation by design approach: characterization and in-vitro evaluation | |
| KR20150030971A (ko) | 난용성 의약품의 수용액상 에멀젼 조성물 및 이의 제조방법 | |
| Kim et al. | Preparation and characterization of cytarabine-loaded w/o/w multiple emulsions | |
| CN106109411A (zh) | 姜黄素滴眼液及其制备方法 | |
| CN112135603A (zh) | 包含奈必洛尔的药物组合物 | |
| Chan et al. | A perfluorobutylpentane (F4H5)‐based solution for the removal of residual emulsified silicone oil | |
| JP2003505424A5 (zh) | ||
| Sk et al. | Micro emulsions: An overview and pharmaceutical applications | |
| TW201938141A (zh) | 基於脂質的眼用乳劑 | |
| EP4026538A1 (en) | Ophthalmic pharmaceutical composition, preparation methods and uses of same | |
| Chaudhary et al. | Role of nanoemulsion as drugs delivery systems in opthalmology: A Comprehensive review | |
| KR960700724A (ko) | 킷트 형태의 약제학적 조성물(Pharmaceutical composition in the form of a Kit) | |
| Dewangan et al. | Nanosized emulsions as a drug carrier for ocular drug delivery: a review | |
| JP7385881B2 (ja) | オキシカム系薬物含有注射剤 | |
| JP7512198B2 (ja) | 脂質ベースの眼科用エマルジョン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190918 Address after: 100005 Beijing city Dongcheng District dongjiaominhang 1 Applicant after: Beijin Tongren Hospital, Attached to Capital Medical Univ. Applicant after: Beijing Tongren Medical Science and Technology Development Company Address before: 100005 Beijing city Dongcheng District dongjiaominhang 1 Applicant before: Beijin Tongren Hospital, Attached to Capital Medical Univ. Applicant before: Beijing Shibao Ophthalmic Equipment Engineering Technology Research Center Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161116 |
|
| RJ01 | Rejection of invention patent application after publication |